At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the interim analysis of PROCEDE−1000, a prospective registry evaluating the impact of Prolaris®, a cell cycle progression (CCP) test, on personalising treatment decisions following biopsy in newly diagnosed patients with prostate cancer.
Allergy & Immunology
